KYMERA THERAPEUTICS INC (KYMR) Stock Fundamental Analysis

NASDAQ:KYMR • US5015751044

91.35 USD
-3.68 (-3.87%)
At close: Feb 27, 2026
91.35 USD
0 (0%)
After Hours: 2/27/2026, 8:15:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, KYMR scores 2 out of 10 in our fundamental rating. KYMR was compared to 520 industry peers in the Biotechnology industry. KYMR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KYMR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year KYMR has reported negative net income.
  • KYMR had a negative operating cash flow in the past year.
  • In the past 5 years KYMR always reported negative net income.
  • KYMR had a negative operating cash flow in each of the past 5 years.
KYMR Yearly Net Income VS EBIT VS OCF VS FCFKYMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

  • KYMR's Return On Assets of -26.78% is fine compared to the rest of the industry. KYMR outperforms 68.58% of its industry peers.
  • With a decent Return On Equity value of -31.19%, KYMR is doing good in the industry, outperforming 74.71% of the companies in the same industry.
Industry RankSector Rank
ROA -26.78%
ROE -31.19%
ROIC N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
KYMR Yearly ROA, ROE, ROICKYMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • KYMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYMR Yearly Profit, Operating, Gross MarginsKYMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for KYMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KYMR Yearly Shares OutstandingKYMR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KYMR Yearly Total Debt VS Total AssetsKYMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • KYMR has an Altman-Z score of 26.38. This indicates that KYMR is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 26.38, KYMR belongs to the best of the industry, outperforming 90.80% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that KYMR is not too dependend on debt financing.
  • KYMR's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. KYMR outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.38
ROIC/WACCN/A
WACC8.61%
KYMR Yearly LT Debt VS Equity VS FCFKYMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • KYMR has a Current Ratio of 7.38. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
  • KYMR has a Current ratio of 7.38. This is in the better half of the industry: KYMR outperforms 71.65% of its industry peers.
  • KYMR has a Quick Ratio of 7.38. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
  • KYMR has a better Quick ratio (7.38) than 71.65% of its industry peers.
Industry RankSector Rank
Current Ratio 7.38
Quick Ratio 7.38
KYMR Yearly Current Assets VS Current LiabilitesKYMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • KYMR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.90%.
EPS 1Y (TTM)-26.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-61.18%

3.2 Future

  • Based on estimates for the next years, KYMR will show a small growth in Earnings Per Share. The EPS will grow by 4.51% on average per year.
  • Based on estimates for the next years, KYMR will show a very strong growth in Revenue. The Revenue will grow by 32.51% on average per year.
EPS Next Y-4.91%
EPS Next 2Y-6.06%
EPS Next 3Y-6.79%
EPS Next 5Y4.51%
Revenue Next Year-11.11%
Revenue Next 2Y-5.53%
Revenue Next 3Y-7.84%
Revenue Next 5Y32.51%

3.3 Evolution

KYMR Yearly Revenue VS EstimatesKYMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
KYMR Yearly EPS VS EstimatesKYMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KYMR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KYMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYMR Price Earnings VS Forward Price EarningsKYMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYMR Per share dataKYMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • KYMR's earnings are expected to decrease with -6.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.06%
EPS Next 3Y-6.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for KYMR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (2/27/2026, 8:15:04 PM)

After market: 91.35 0 (0%)

91.35

-3.68 (-3.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners106.53%
Inst Owner Change9.75%
Ins Owners1.29%
Ins Owner Change0.62%
Market Cap7.29B
Revenue(TTM)N/A
Net Income(TTM)-295.12M
Analysts86.21
Price Target114.77 (25.64%)
Short Float %12.06%
Short Ratio8.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.81%
Min EPS beat(2)-14.98%
Max EPS beat(2)-14.63%
EPS beat(4)1
Avg EPS beat(4)-7.19%
Min EPS beat(4)-14.98%
Max EPS beat(4)12.26%
EPS beat(8)5
Avg EPS beat(8)6.01%
EPS beat(12)6
Avg EPS beat(12)1.09%
EPS beat(16)6
Avg EPS beat(16)-3.08%
Revenue beat(2)0
Avg Revenue beat(2)-68.8%
Min Revenue beat(2)-85.7%
Max Revenue beat(2)-51.89%
Revenue beat(4)1
Avg Revenue beat(4)-15.73%
Min Revenue beat(4)-85.7%
Max Revenue beat(4)113.36%
Revenue beat(8)3
Avg Revenue beat(8)-5.2%
Revenue beat(12)4
Avg Revenue beat(12)-13.21%
Revenue beat(16)4
Avg Revenue beat(16)-18.16%
PT rev (1m)1.9%
PT rev (3m)47.7%
EPS NQ rev (1m)1.95%
EPS NQ rev (3m)-0.42%
EPS NY rev (1m)-1.61%
EPS NY rev (3m)-3.66%
Revenue NQ rev (1m)1.21%
Revenue NQ rev (3m)-0.77%
Revenue NY rev (1m)0.61%
Revenue NY rev (3m)-25.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 166.66
P/FCF N/A
P/OCF N/A
P/B 7.7
P/tB 7.7
EV/EBITDA N/A
EPS(TTM)-3.68
EYN/A
EPS(NY)-3.86
Fwd EYN/A
FCF(TTM)-2.89
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS0.55
BVpS11.86
TBVpS11.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.78%
ROE -31.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.56%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.38
Quick Ratio 7.38
Altman-Z 26.38
F-Score2
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)412.2%
Cap/Depr(5y)364.06%
Cap/Sales(3y)25.74%
Cap/Sales(5y)21.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.23%
EPS Next Y-4.91%
EPS Next 2Y-6.06%
EPS Next 3Y-6.79%
EPS Next 5Y4.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-61.18%
Revenue Next Year-11.11%
Revenue Next 2Y-5.53%
Revenue Next 3Y-7.84%
Revenue Next 5Y32.51%
EBIT growth 1Y-68.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.44%
EBIT Next 3Y-16.22%
EBIT Next 5YN/A
FCF growth 1Y-32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.45%
OCF growth 3YN/A
OCF growth 5YN/A

KYMERA THERAPEUTICS INC / KYMR FAQ

Can you provide the ChartMill fundamental rating for KYMERA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to KYMR.


What is the valuation status of KYMERA THERAPEUTICS INC (KYMR) stock?

ChartMill assigns a valuation rating of 0 / 10 to KYMERA THERAPEUTICS INC (KYMR). This can be considered as Overvalued.


Can you provide the profitability details for KYMERA THERAPEUTICS INC?

KYMERA THERAPEUTICS INC (KYMR) has a profitability rating of 1 / 10.


What is the expected EPS growth for KYMERA THERAPEUTICS INC (KYMR) stock?

The Earnings per Share (EPS) of KYMERA THERAPEUTICS INC (KYMR) is expected to decline by -4.91% in the next year.